Pharmacology & Drug Development Congress
  • Follow

Accepted Abstracts

Adiponectin as a Potential Biomarker of Diabetic Nephropathy

Ayman EL-Zarka1*, Aida Soliman1, Sahar Bessa2, Tarek Mohamed2
1Suez Canal University, Egypt
2Tanta University, Egypt

Citation: EL-Zarka A, Soliman A, Bessa S, Mohamed T (2020) Adiponectin as a Potential Biomarker of Diabetic Nephropathy. SciTech Central Pharma 2020. Mauritius 
 

Received: March 11, 2020         Accepted: March 13, 2020         Published: March 13, 2020

Abstract

Diabetic Nephropathy (DN) is a progressive kidney disease associated with diabetes mellitus that may lead to end-stage renal disease. Adiponectin (ADP) is a protein hormone produced by white adipose tissue and has vasoprotective properties. Adiponectin level attributes to and associates with diabetic complications. Herein, we assess the potentiality of detecting ADP level as a DN marker. This study included sixty age and sex-matched subjects which were subdivided into three groups: twenty healthy(control) subjects, twenty type 2 diabetes patients with nephropathy(microalbuminuria 30-300 mg/dL) and twenty type 2 diabetes patients without nephropathy (normoalbuminuria<30mg/dL). Mean serum ADP levels were significantly increased in all patients with type 2 diabetes with or without nephropathy as compared to the control group with higher levels in those with nephropathy. Serum ADP levels were positively correlated with fasting blood glucose, glycosylated haemoglobin (HbA1c), microalbuminuria, serum creatinine and urea. The most independent risk factors for occurrence of microvascular complications may reflect the role of ADP as a predictor and prognostic marker of DN among patients with type 2 diabetes.